港股詳情

本页面由TTMF Limited提供服务

百利天恆待上市

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：4.22億

香港流通股本：4.22億

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：-14.94%

總資產收益率：-5.41%

市淨率：0.00

市盈率(LYR):- -

市銷率: 0.00

1

开始申购

11/07

2

申購截止

11/12 09:30

3

公布中签

11/13

4

暗盘

12/31 16:15 - 18:30

5

挂牌上市

11/17

總覽公司新聞資訊公告

价格范围

347.50 ~ 389.00 HKD

发行价

- -

发行量

863.43萬

预计市值

1,464.74億 ~ 1,639.67億 HKD

最低申购数量

100

承销商

高盛(亚洲)有限责任公司

查看招股说明书

新聞資訊

四川首富的百利天恒，正遭戴維斯雙殺！

百利天恒：增減持計劃可實施日期提醒

百利天恒回購32萬股金額9985萬元

中信證券剛給出千元目標價百利天恒業績就報虧了

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02615"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02615","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恆","latestPrice":0,"timestamp":1770706617926,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"02-10 14:56:57","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.204,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1770687000000,1770696000000],[1770699600000,1770710400000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恆","latestPrice":288.69,"timestamp":1770706614000,"preClose":271.35,"halted":0,"volume":3401700,"delay":0,"premium":"-100.00"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","floatShares":421508117,"roa":"-5.41%","roe":"-14.94%","lyrEps":0,"shares":421508117,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","psRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.204,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/02615\",,undefined,":{"id":9063,"type":"COMMON","ipoName":"02615-IPO","symbol":"02615","companyName":"百利天恆","market":"HK","currency":"HKD","status":"CANCELLED","underwriter":"高盛(亚洲)有限责任公司","lotSize":100,"minQty":100,"expectedOfferingSize":8634300,"openingDate":1762479000000,"closingDate":1762911000000,"commonClosingDate":1762911000000,"allotmentDate":1762963200000,"listDate":1763308800000,"marginable":true,"latestPrice":389,"minPrice":347.5,"maxPrice":389,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","allowedQuantities":[100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700],"recommend":false,"isHint":false,"interestStartDate":1762876800000,"interestEndDate":1762876800000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1763108100000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[],"latestClosingDate":1770706617970,"subscribedFinanceRatio":19.93,"subscribedRatio":19.93,"forecastRatio":24.31,"raiseMoney":335900000,"totalMargin":6694640000,"quoteInfoUpdatedAt":1770621923881,"prospectusUpdatedAt":1762928848000,"forecastMarketValue":155220364085.25,"minForecastMarketValue":146474070657.5,"maxForecastMarketValue":163966657513,"sharesOutstanding":421508117,"business":"公司是一家具備早期研發、臨床開發、生產及商業化能力的綜合醫療企業集團。","greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"tradable":false,"showClawback":false},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02615\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610689748","title":"四川首富的百利天恒，正遭戴維斯雙殺！","url":"https://stock-news.laohu8.com/highlight/detail?id=2610689748","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610689748?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 14:42","pubTimestamp":1770619320,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　传统主业萎缩，创新药持续烧钱，公司面临业绩及股价下滑的双重压力。　　百利天恒曾经凭借一笔巨额海外授权收入迅速扭亏为盈并且市值飙升，实控人朱义晋升四川首富。　　百利天恒2025年的业绩预告，向市场泼了一盆冷水。　　去年9月份，百利天恒顺利完成了一次转增发，实际募资净额37.29亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-02-09/doc-inhmfcph5404148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91194","BK0239","688506","02615"],"gpt_icon":0},{"id":"2610506855","title":"百利天恒：增減持計劃可實施日期提醒","url":"https://stock-news.laohu8.com/highlight/detail?id=2610506855","media":"大智慧idata","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610506855?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 08:00","pubTimestamp":1770595207,"startTime":"0","endTime":"0","summary":"公司其他股东OAP III (HK) Limited计划自2026年02月09日起至2026年05月08日，拟减持不超过412.87万股，占总股本比例1.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209080917a48c90b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209080917a48c90b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91194","02615"],"gpt_icon":0},{"id":"2608822501","title":"百利天恒回購32萬股 金額9985萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608822501","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608822501?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 18:17","pubTimestamp":1770113866,"startTime":"0","endTime":"0","summary":"2月3日，百利天恒（688506）发布公告，截至2026年1月31日，公司已回购32万股，占总股本的0.08%，回购资金总额为9985万元，回购价格区间为279.72元/股至345.24元/股。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033640244377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","91194","02615","688506"],"gpt_icon":0},{"id":"2608812821","title":"中信證券剛給出千元目標價 百利天恒業績就報虧了","url":"https://stock-news.laohu8.com/highlight/detail?id=2608812821","media":"投资AB面","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608812821?lang=zh_tw&edition=fundamental","pubTime":"2026-02-02 16:35","pubTimestamp":1770021300,"startTime":"0","endTime":"0","summary":"若以中信证券给出的1322元/股的价位来计算，百利天恒的总市值将突破5400亿元，有望超越恒瑞医药、百济神州，成为A股“医药一哥”。不过就在中信证券给出千元目标价后没几天，百利天恒业绩就报亏了。然而，由于百利天恒目前收入主要依赖iza-bren这一主要产品，导致公司业绩在没有新的收入后大幅下滑。倘若iza-bren能够顺利上市的话，百利天恒的业绩有望得到改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020216520497a476fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020216520497a476fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91194","02615"],"gpt_icon":0}],"pageSize":4,"totalPage":39,"pageCount":1,"totalSize":154,"code":"91000000","status":"200"}]}}